18F-Clofarabine for Metastatic Cancer

Phase-Based Progress Estimates
Metastatic Cancer+2 More18F-Clofarabine - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test whether a new imaging agent, 18F-Clofarabine, can be used to show pyrimidine metabolism in order to better predict whether cancer drugs will be effective.

Eligible Conditions
  • Metastatic Cancer
  • Adenocarcinoma
  • Cancer

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: up to 60 minutes after CFA PET

Month 12
Correlate CFA uptake with OS
Correlate CFA uptake with PFS
Month 3
Correlate CFA uptake with conventional imaging
up to 60 minutes after CFA PET
Evaluate CFA as a PET imaging agent
within 48 hrs of radiotracer administration
Adverse Events

Trial Safety

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

15 Total Participants · 1 Treatment Group

Primary Treatment: 18F-Clofarabine · No Placebo Group · Phase < 1

Experimental Group · 1 Intervention: 18F-Clofarabine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 60 minutes after cfa pet

Who is running the clinical trial?

Omar MianLead Sponsor
Omar Mian, MDPrincipal InvestigatorCleveland Clinic, Case Comprehensive Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a histologically or cytologically proven carcinoma or adenocarcinoma.
You are at least 18 years old.
Total serum bilirubin < 2.0 x ULN.
You have a platelet count of at least 75,000/uL.
Hemoglobin > or = 8.0 g/dL.

Who else is applying?

What state do they live in?
What portion of applicants met pre-screening criteria?
Met criteria100.0%